BRAF and melanoma: The combination of nivolumab and ipilimumab leads to the best outcome, and the Food and Drug Administration (FDA) approved this cocktail as the best treatment for both advanced BRAF-negative melanoma patients [96,101,102] and for melanoma patients with BRAF mutation [97].